Byron Ladd, MD
Ophthalmology · Richmond, VANPI 1619086634
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,756 of the $7,336 with a category attached, or 64.8%. 16 manufacturers reported payments, led by Notal Vision, Inc. at 37.6% of the total. 2025 is the largest year on record at $2,468, 4.0 times the $618 reported in 2019. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 107 payments — averaging $68.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Notal Vision, Inc.$3K
- Ocular Therapeutix, Inc.$2K
- Genentech USA, Inc.$558
- Alimera Sciences, Inc.$476
- Regeneron Healthcare Solutions, Inc.$453
- Astellas Pharma US Inc$305
- plus $1K from 10 others
Across 658 payments — averaging $37.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$24K
What the payments were for
- Consulting fees$1,50020%
- Speaking & faculty fees$1,08015%
- Food & beverage$4,75665%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Notal Vision, Inc. | 24 | $2,758 |
| Ocular Therapeutix, Inc. | 4 | $1,552 |
| Genentech USA, Inc. | 15 | $558 |
| Alimera Sciences, Inc. | 10 | $476 |
| Regeneron Healthcare Solutions, Inc. | 13 | $453 |
| Astellas Pharma US Inc | 7 | $305 |
| Alcon | 5 | $226 |
| AbbVie(2 entities) | 12 | $215 |
| Genentech, Inc. | 2 | $210 |
| Novartis | 4 | $193 |
| Harrow Eye, LLC | 5 | $129 |
| Coherus Oncology, Inc. | 2 | $129 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,336 in reported general payments places this provider in the 90th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 48 | $21,588 |
| Bromfenac Sodium | 40 | $6,594 |
| Prednisolone Acetate | 109 | $4,379 |
| Timolol Maleate | 16 | $1,078 |
| Ofloxacin | 56 | $516 |
| Latanoprost | 42 | $271 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $216 |
| ErythromycinErythromycin Base | 20 | $205 |
| Brimonidine Tartrate | 14 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $19 | $21,58848 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Richmond
- Ethnie JonesRichmond$2M
- Thomas JenkinsRichmond$26K
- Jessica RandolphRichmond$18K
- Nikisha RichardsRichmond$16K
- Tam DangRichmond$9K
- Bryan SchwentRichmond$7K
- Rishi ParikhRichmond$6K
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.